The Patient Safety Screener-3 (PSS-3) is a brief instrument designed to screen for suicide-related risk. One item on the scale (item 1) assesses depressive mood but is not included in the PSS-3 total score. This nationwide cross-sectional study of resident physicians in Japan examined the association between endorsement of PSS-3 item 1 and depressive symptom severity measured by the Patient Health Questionnaire-9 (PHQ-9), and characterized the suicide-related risk captured by PSS-3 total positivity.
The authors aimed to determine whether item 1 endorsement corresponds with PHQ-9 positivity and to compare how PSS-3 total positivity and PHQ-9 item 9 positivity relate to scores on the Short-form Scale for Suicide Ideation (SIS-6).
This analysis used a nationwide cross-sectional survey conducted among resident physicians in Japan. The report specifies the instruments used: the PSS-3, the PHQ-9 to assess depressive symptom severity and define PHQ-9 positivity (score ≥10), and the SIS-6 to quantify suicide ideation severity.
Associations between endorsement of PSS-3 item 1 and PHQ-9 scores were tested using the Wilcoxon rank-sum test. Diagnostic performance of PSS-3 item 1 for identifying PHQ-9 positivity was evaluated (sensitivity and specificity reported). Comparisons of SIS-6 scores were made according to PSS-3 total positivity and PHQ-9 item 9 positivity. Receiver operating characteristic analyses and measures such as area under the curve (AUC) and Youden index were used to compare discrimination of SIS-6 for the two positivity definitions.
Ethical oversight was provided by the Ethics Review Board of the Japan Institute for Advancement of Medical Education Program (approval number: 25-11). The manuscript states that participant consent and relevant reporting guidelines were followed. Raw data are not publicly available owing to privacy or ethical restrictions but are available from the corresponding author upon reasonable request.
A total of 1,844 resident physicians were included in the study sample. Among these participants, 443 physicians (24.0%) endorsed PSS-3 item 1, which assesses depressive mood. A smaller subset, 47 physicians (2.5%), met criteria for PSS-3 total positivity.
The manuscript reports comparisons of PHQ-9 scores by endorsement of PSS-3 item 1 and documents the diagnostic properties of item 1 relative to PHQ-9 positivity, as described below.
Using PHQ-9 positivity (score ≥10) as the reference standard, endorsement of PSS-3 item 1 demonstrated a sensitivity of 79.3% and a specificity of 79.5% for detecting PHQ-9–defined depressive symptoms. These diagnostic performance metrics indicate that item 1 identifies a substantial proportion of those meeting the PHQ-9 threshold while maintaining moderate specificity.
The Wilcoxon rank-sum test was used to evaluate the association between endorsement of item 1 and PHQ-9 scores; the report indicates a statistically significant relationship, consistent with item 1 reflecting depressive symptom severity, though the manuscript does not reproduce all test statistics in the abstract.
Suicide ideation severity measured by the Short-form Scale for Suicide Ideation (SIS-6) differed markedly by PSS-3 total positivity. The median SIS-6 score in the PSS-3 total-positive group was 6 (interquartile range [IQR] 5–9) compared with a median of 0 (IQR 0–1) in the PSS-3 total-negative group; this difference reached statistical significance (p < 0.001).
Receiver operating characteristic analyses showed that the SIS-6 had a higher area under the curve for discriminating PSS-3 total positivity than for discriminating PHQ-9 item 9 positivity. Reported values were AUC 0.961 for PSS-3 total positivity (with an optimal SIS-6 cutoff of 3) and AUC 0.907 for PHQ-9 item 9 positivity (with an optimal SIS-6 cutoff of 2). The higher AUC and Youden index for PSS-3 total positivity suggest that PSS-3 total positivity corresponds to a more severe spectrum of suicide-related risk than PHQ-9 item 9 positivity alone.
In this sample of Japanese resident physicians, endorsement of PSS-3 item 1 was common (24.0%), and PSS-3 total positivity was less frequent (2.5%). PSS-3 item 1 showed moderate-to-high sensitivity and specificity for PHQ-9 positivity (≥10), indicating that the single depressive mood item relates meaningfully to depressive symptom severity as assessed by PHQ-9.
PSS-3 total positivity identified a group with substantially higher SIS-6 scores than those who were total-negative, and the SIS-6 discriminated PSS-3 total positivity more strongly than PHQ-9 item 9 positivity. These findings led the authors to conclude that the PSS-3 may support brief, simultaneous screening for depressive symptoms and suicide-related risk and that PSS-3 total positivity may capture a more severe subset of suicide-related risk than PHQ-9 item 9 alone.
Clinically, the authors suggest PSS-3 could facilitate identification of individuals who require further mental health assessment. The manuscript does not provide implementation algorithms or longitudinal outcome data; it focuses on cross-sectional associations and diagnostic performance within the surveyed sample.
The study received ethical approval from the named ethics board (approval number 25-11). Several authors disclosed receipt of honoraria related to the Japan Institute for Advancement of Medical Education Program (JAMEP); HT, SF, YN, and YT were not involved in data analysis. Funding sources declared in the manuscript included multiple foundations and grant agencies. Raw data are not publicly available because of privacy or ethical constraints but can be requested from the corresponding author.
Overall, the report presents evidence that the PSS-3 and its depressive mood item are associated with established measures of depression and that PSS-3 total positivity aligns with higher suicide ideation severity as measured by SIS-6, supporting its potential utility for brief screening in clinical or educational settings.